Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 49.79 Billion KRW | -23.64% |
| 2022 | 62.27 Billion KRW | 64.52% |
| 2021 | 37.1 Billion KRW | -3.41% |
| 2020 | 39.65 Billion KRW | -14.16% |
| 2019 | 47.44 Billion KRW | 11.94% |
| 2018 | 40.98 Billion KRW | 26.66% |
| 2017 | 33.89 Billion KRW | -12.07% |
| 2016 | 36.61 Billion KRW | 29.78% |
| 2015 | 28.78 Billion KRW | 14.57% |
| 2014 | 22.12 Billion KRW | 24.85% |
| 2013 | 19.58 Billion KRW | 14.32% |
| 2012 | 16.55 Billion KRW | 5.88% |
| 2011 | 16.26 Billion KRW | -27.31% |
| 2010 | 24.84 Billion KRW | 32.45% |
| 2009 | 16.77 Billion KRW | 27.13% |
| 2008 | 12.52 Billion KRW | 18.49% |
| 2007 | 11.98 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 19.49 Billion KRW | 51.3% |
| 2024 Q2 | 2.86 Billion KRW | -77.83% |
| 2023 Q3 | 60 Billion KRW | -8.38% |
| 2023 Q2 | 65.49 Billion KRW | 359.32% |
| 2023 Q1 | 14.26 Billion KRW | 45.13% |
| 2023 FY | - KRW | -23.64% |
| 2023 Q4 | 12.12 Billion KRW | -79.8% |
| 2022 Q1 | 19.4 Billion KRW | 18.65% |
| 2022 FY | - KRW | 64.52% |
| 2022 Q2 | 15.61 Billion KRW | -19.53% |
| 2022 Q3 | 20.37 Billion KRW | 30.47% |
| 2022 Q4 | 9.82 Billion KRW | -51.77% |
| 2021 FY | - KRW | -3.41% |
| 2021 Q1 | 2.47 Billion KRW | -58.0% |
| 2021 Q2 | 9.16 Billion KRW | 270.56% |
| 2021 Q4 | 16.35 Billion KRW | 40.41% |
| 2021 Q3 | 11.64 Billion KRW | 27.06% |
| 2020 Q1 | 14.12 Billion KRW | 3.9% |
| 2020 Q4 | 5.88 Billion KRW | -38.01% |
| 2020 Q3 | 9.49 Billion KRW | -17.58% |
| 2020 FY | - KRW | -14.16% |
| 2020 Q2 | 11.52 Billion KRW | -18.37% |
| 2019 Q3 | 11.54 Billion KRW | -0.36% |
| 2019 FY | - KRW | 11.94% |
| 2019 Q2 | 11.58 Billion KRW | 4.62% |
| 2019 Q4 | 13.59 Billion KRW | 17.69% |
| 2019 Q1 | 11.07 Billion KRW | -3.96% |
| 2018 Q3 | 9.75 Billion KRW | -4.81% |
| 2018 FY | - KRW | 26.66% |
| 2018 Q1 | 11.19 Billion KRW | 77.92% |
| 2018 Q4 | 11.53 Billion KRW | 18.28% |
| 2018 Q2 | 10.24 Billion KRW | -8.48% |
| 2017 Q1 | 6.87 Billion KRW | -44.08% |
| 2017 Q4 | 6.29 Billion KRW | -42.23% |
| 2017 FY | - KRW | -12.07% |
| 2017 Q3 | 10.89 Billion KRW | 10.49% |
| 2017 Q2 | 9.85 Billion KRW | 43.43% |
| 2016 FY | - KRW | 29.78% |
| 2016 Q2 | 8.78 Billion KRW | 29.57% |
| 2016 Q1 | 6.77 Billion KRW | -20.52% |
| 2016 Q3 | 10.24 Billion KRW | 16.66% |
| 2016 Q4 | 12.28 Billion KRW | 19.97% |
| 2015 FY | - KRW | 14.57% |
| 2015 Q1 | 6.82 Billion KRW | -13.9% |
| 2015 Q4 | 8.52 Billion KRW | 44.21% |
| 2015 Q3 | 5.91 Billion KRW | -25.16% |
| 2015 Q2 | 7.9 Billion KRW | 15.74% |
| 2014 Q2 | 5.43 Billion KRW | 27.07% |
| 2014 Q1 | 4.27 Billion KRW | -28.11% |
| 2014 FY | - KRW | 24.85% |
| 2014 Q4 | 7.92 Billion KRW | -2.69% |
| 2014 Q3 | 8.14 Billion KRW | 49.92% |
| 2013 Q2 | 5.94 Billion KRW | 63.55% |
| 2013 Q3 | 5.13 Billion KRW | -13.71% |
| 2013 Q4 | 5.94 Billion KRW | 15.87% |
| 2013 FY | - KRW | 14.32% |
| 2013 Q1 | 3.63 Billion KRW | -42.83% |
| 2012 Q3 | 4.02 Billion KRW | 12.34% |
| 2012 Q4 | 6.36 Billion KRW | 58.01% |
| 2012 FY | - KRW | 5.88% |
| 2012 Q1 | 2.3 Billion KRW | 0.0% |
| 2012 Q2 | 3.58 Billion KRW | 55.35% |
| 2011 Q1 | 5.98 Billion KRW | 87.56% |
| 2011 Q2 | 4.9 Billion KRW | -18.13% |
| 2011 Q3 | 3.51 Billion KRW | -28.3% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | - KRW | -27.31% |
| 2010 Q2 | 6.23 Billion KRW | -8.6% |
| 2010 Q1 | 6.82 Billion KRW | 121.73% |
| 2010 FY | - KRW | 32.45% |
| 2010 Q3 | 7.22 Billion KRW | 15.89% |
| 2010 Q4 | 3.19 Billion KRW | -55.81% |
| 2009 Q4 | 3.07 Billion KRW | -51.91% |
| 2009 FY | - KRW | 27.13% |
| 2009 Q3 | 6.39 Billion KRW | 40.7% |
| 2009 Q2 | 4.54 Billion KRW | 25.22% |
| 2009 Q1 | 3.63 Billion KRW | -15.29% |
| 2008 Q3 | 2.37 Billion KRW | -32.16% |
| 2008 Q2 | 3.49 Billion KRW | -7.89% |
| 2008 Q1 | 3.79 Billion KRW | 95.94% |
| 2008 FY | - KRW | 18.49% |
| 2008 Q4 | 4.28 Billion KRW | 80.87% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | 1.93 Billion KRW | -31.12% |
| 2007 Q3 | 2.81 Billion KRW | -15.46% |
| 2007 Q2 | 3.32 Billion KRW | -10.31% |
| 2007 Q1 | 3.7 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -924.897% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 64.777% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 177.758% |
| HANDOK Inc. | 35.06 Billion KRW | -41.995% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 4903.602% |
| Yuhan Corporation | 127.43 Billion KRW | 60.926% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -32.707% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 329.592% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 84.6% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -897.79% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -229.357% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -1355.519% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -1000.056% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -40.316% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -924.897% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 369.562% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -659.622% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 201.017% |
| JW Holdings Corporation | 187.88 Billion KRW | 73.498% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 197.198% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 82.444% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 44.191% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 234.333% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -276.945% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -320.98% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -166.917% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -924.897% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 9.423% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 69.806% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 44.191% |
| Yuhan Corporation | 127.43 Billion KRW | 60.926% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -48.743% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -550.903% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 35.358% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 44.191% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -35.918% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 29.651% |
| CKD Bio Corp. | -1.63 Billion KRW | 3153.951% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -52.92% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -35.269% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 234.333% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 20.055% |
| Boryung Corporation | 114.28 Billion KRW | 56.432% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 262.891% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -229.357% |
| JW Lifescience Corporation | 50.82 Billion KRW | 2.039% |